CGMedTec has signed a CDMO agreement with Kolon Pharma to commercialize human extracellular matrix (hECM)-based tissue products for skin booster applications, marking the first external expansion of CGMedTec's human tissue value chain and a key milestone for its CDMO platform business.
Deal details
The agreement, signed on the 15th, covers the development, production, and supply of hECM-based human tissue products intended for skin booster use. CGMedTec will handle product development, manufacturing, quality control, regulatory affairs, and supply chain management, while Kolon Pharma will manage sales and distribution primarily through domestic hospitals and clinics.
Strategic rationale
Kolon Pharma aims to expand its aesthetic business portfolio through this collaboration. For CGMedTec, the deal extends its human tissue manufacturing platform to external clients for the first time, signaling a full-scale launch of its CDMO platform business.
What buyers should watch
Overseas distributors and clinic buyers should monitor this partnership as it could lead to new hECM-based skin booster products entering the Korean market. The companies plan to scale supply, build long-term cooperation, and develop new product lines based on market demand and business performance.
Executive comment
"This collaboration with Kolon Pharma is the first case of expanding CGMedTec's human tissue-based business value chain to an external client, and an important turning point that marks the full-fledged launch of our human tissue CDMO platform business," said CGMedTec CEO Yoo Hyun-seung. "We will leverage our accumulated manufacturing infrastructure, quality control, and regulatory response capabilities to become a strategic partner supporting our clients' successful commercialization."
Source: Read the original report | Published: June 16, 2026